Allogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality

• Post author:andrewkaretas
• Post published:May 18, 2022
• Post category:PLATFORM/Scientific Publications

Continue ReadingAllogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma

• Post author:andrewkaretas
• Post published:April 20, 2022
• Post category:CD70/Scientific Publications

Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma

• Post author:andrewkaretas
• Post published:April 18, 2022
• Post category:CD70/Scientific Publications

Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

• Post author:andrewkaretas
• Post published:March 18, 2022
• Post category:BCMA/Scientific Publications

Continue ReadingAllogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR

• Post author:andrewkaretas
• Post published:December 21, 2021
• Post category:CD19/Scientific Publications

Continue ReadingALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR

UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

• Post author:andrewkaretas
• Post published:December 18, 2021
• Post category:BCMA/Scientific Publications

Continue ReadingUNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

• Post author:andrewkaretas
• Post published:December 17, 2021
• Post category:CD19/Scientific Publications

Continue ReadingALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Test

• Post author:andrewkaretas
• Post published:October 5, 2021
• Post category:Uncategorized

Continue ReadingTest

Zea M.

• Post author:andrewkaretas
• Post published:September 29, 2021
• Post category:reasons

“Giving people the most precious thing we have together - time.“ — Zea M.

Continue ReadingZea M.

Thomas P.

• Post author:andrewkaretas
• Post published:September 29, 2021
• Post category:reasons

“I am dedicating this to my son. When I was his age, the thought of administering genetically engineered allogeneic T cells to cancer patients was science fiction. Today, that pipedream…

Continue ReadingThomas P.